title: Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program.
abstract: BACKGROUND
  The role of histology in the targeted management of nonsmall cell lung cancer (NSCLC) has garnered renewed attention in recent years. We provide contemporary population-based estimates of survival and an assessment of important prognostic factors in stage IV NSCLC by major histologic subtype.
  
  
  METHODS
  Using data from the Surveillance, Epidemiology and End Results (SEER) Program, we stratified 51,749 incident stage IV NSCLC patients (1988-2003 with follow-up through 2006) by major histologic subtype. We used Kaplan-Meier and Cox proportional hazards methods to describe overall survival and the prognostic influence of select patient, tumor, and treatment characteristics for each histologic subgroup.
  
  
  RESULTS
  Survival was highest in patients with bronchioloalveolar adenocarcinoma (1-year survival: 29.1%) and lowest in those with large cell tumors (1-year survival: 12.8%). Diagnosis in later years, female gender, younger age, either Asian/Pacific Islander or Hispanic race/ethnicity, lower tumor grade, and surgery or beam radiation as part of first-line treatment were generally independently associated with a decreased risk of death, but the prognostic significance of some of these factors (age, ethnicity, tumor grade) varied according to histologic subtype.
  
  
  CONCLUSIONS
  Findings demonstrate a poor prognosis across histologic subtypes in stage IV NSCLC patients but highlight differences in both absolute survival and the relative importance of select prognostic factors by histologic subclassification. More research using other sources of population-based data could help clarify the role of histology in the presentation, management, and prognosis of late-stage NSCLC.
authors: Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA;
authors: Karynsa
authors: K
authors: Cetin
authors: David S
authors: DS
authors: Ettinger
authors: Yong-Jiang
authors: YJ
authors: Hei
authors: Cynthia D
authors: CD
authors: O'Malley
references: Chest. 2006 Dec;130(6):1796-802
references: 17166999
references: Chest. 1999 May;115(5):1232-6
references: 10334132
references: Chest. 2005 Mar;127(3):768-77
references: 15764756
references: J Clin Oncol. 2007 May 1;25(13):1705-12
references: 17470862
references: Br J Cancer. 2008 Dec 2;99(11):1757-62
references: 18985035
references: J Clin Oncol. 2007 Feb 10;25(5):561-70
references: 17290066
references: J Thorac Oncol. 2008 Dec;3(12):1468-81
references: 19057275
references: J Thorac Cardiovasc Surg. 2000 Jan;119(1):21-6
references: 10612756
references: J Clin Oncol. 2004 Dec 15;22(24):4971-8
references: 15611512
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Cancer. 2005 Jun 15;103(12):2566-74
references: 15852359
references: Ann Thorac Surg. 2004 Jul;78(1):209-15; discussion 215
references: 15223430
references: Ann Oncol. 2002 Jul;13(7):1087-93
references: 12176788
references: J Natl Cancer Inst. 2004 Jul 21;96(14):1105-7
references: 15265973
references: Chest. 2001 Jul;120(1):55-63
references: 11451816
references: J Thorac Oncol. 2007 Mar;2(3):180-90
references: 17410040
references: J Thorac Oncol. 2009 Sep;4(9):1083-93
references: 19652625
references: Lung Cancer. 2001 Aug-Sep;33(2-3):203-11
references: 11551415
references: J Clin Oncol. 2008 Jul 20;26(21):3485-6
references: 18506022
references: Ann Oncol. 2009 Sep;20(9):1608-1609
references: 19633043
references: J Thorac Oncol. 2009 Oct;4(10):1202-11
references: 19701111
references: Eur J Surg Oncol. 2007 Aug;33(6):763-8
references: 17306497
references: J Clin Oncol. 1997 Aug;15(8):2996-3018
references: 9256144
references: N Engl J Med. 2008 Sep 25;359(13):1367-80
references: 18815398
references: Cancer. 1995 Dec 1;76(11):2343-50
references: 8635041